SLC5A2 and hydrops fetalis: Currently, SGLT2 inhibitors (dapagliflozin or empagliflozin) are also recommended in patients with mildly reduced EF (HFmrEF) and with preserved EF (HFpEF) to reduce the risk of HF hospitalization or cardiovascular death (class I, level A) [79].